Unicocell Biomed Co., Ltd. (referred to as “Unicocell”, stock code: 6794), a company dedicated to the development of stem cell and regenerative medicine products, has recently been granted a Taiwan invention patent by the Taiwan Intellectual Property Office (Patent No. I920005), entitled “A method for inhibiting the polarization of M0 macrophages into M1 macrophages.” The patented technology serves as a functional evaluation platform designed to assess the anti-inflammatory properties of cell-based products.
This technology focuses on the regulation of key cellular states within the immune response, specifically modulating the transition of immune cells from a resting state to a pro-inflammatory phenotype. It enables quantitative evaluation of immunomodulatory biological activity. During the development of stem cell-based therapeutics, this platform can be applied as an analytical tool for evaluating anti-inflammatory activity, supporting functional validation and product characterization. It may also be utilized in research related to chronic inflammation and immune dysregulation.
Regulation of the immune microenvironment is a critical foundation for the development of regenerative medicine and cell therapy products. This patent strengthens Unicocell’s capabilities in immunomodulation and further enhances its functional evaluation platform for stem cell-based therapeutics. The technology also provides supportive tools for investigating mechanisms of action in clinical studies of cell therapies.
Moving forward, the patented technology is expected to be applied across multiple disease areas and product development programs. Unicocell will continue to build its core technological capabilities in regenerative medicine, further strengthening its competitive position and supporting its global development strategy.
Contact: Ray Liu
Phone: 886-2-27922699
Mail: info@unicocell.com